Article
Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations.
Pharmacogenetics and genomics - 1 Apr 2011
Wehland Markus, Bauer Steffen, Brakemeier Susanne, Burgwinkel Philip, Glander Petra, Kreutz Reinhold, Lorkowski Christine, Slowinski Torsten, Neumayer Hans H, Budde Klemens
Abstract excerpt
OBJECTIVES: We investigated the pharmacokinetic and pharmacogenetic implications of conversion from a twice-daily (P-Tac) to a once-daily (A-Tac) tacrolimus (Tac) formulation. METHODS: We analyzed Tac levels in a cohort of 41 renal transplant patients with a stable graft function over a period of 1 year before and after conversion. RESULTS: After conversion, the patients had, on average, significantly lower Tac...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.